Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fred Hutchinson Cancer Research Center
Headquarters: Seattle, WA, United States of America
Website: http://www.fhcrc.org/en.html...
Year Founded: N/A
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 5, 2024
Discovery & Translation
New frontiers in extracellular protein degradation
Six papers detail improved ways to degrade cell-surface cancer proteins through the lysosome
BioCentury | Sep 4, 2024
Discovery & Translation
The inextricable linkage of biomarkers and target discovery
Back to School 2024: How biomarkers can help validate targets while bringing precision medicine to I&I and neurology
BioCentury | Jun 1, 2024
Discovery & Translation
Science Spotlight: Restoring calcium homeostasis for Alzheimer’s, a gene therapy foam, and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 30, 2024
Finance
Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast
Plus: the schizophrenia pipeline and what’s next for Singapore biotech
BioCentury | Jan 26, 2024
Product Development
Growing IL-18 field looks to enhance cell therapies via decoy evasion
As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
BioCentury | Dec 19, 2023
Discovery & Translation
Next-gen gene editing at ASH
Non-Cas9 enzymes and strategies to improve ex vivo and in vivo engineering of hematopoietic cells are among the innovations
BioCentury | May 5, 2023
Emerging Company Profile
Function: using CRISPR to match patients to treatments
San Diego start-up advancing precision oncology with $28 million series A financing led by Andreessen Horowitz and Section 32
BioCentury | Aug 20, 2022
Data Byte
In vivo CAR engineering revs up
Companies delivering DNA- and RNA-encoded CARs aim to sidestep the challenges of ex vivo reprogramming
BioCentury | Aug 4, 2022
Finance
Aug. 3 Quick Takes: Horizon dips after Tepezza sales come up short
Plus AbCellera tightens ties with another VC, and updates from Merck-Eisai, Regeneron, Ipsen and more
BioCentury | May 20, 2022
Discovery & Translation
Precision’s chronic HBV gene therapy; plus Blaze and ASGCT highlights
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 219